Hannah Joseph Hospital Ltd is a Madurai-based multi-specialty neurosciences and trauma care hospital, operating a 133-bed tertiary care facility with allied specialties including Cardiac Sciences, Orthopedics, and Oral & Maxillofacial Surgery. Incorporated in 2011 and converted into a public limited company in 2022, the hospital has established itself as a regional referral centre for complex neurological, neurosurgical and trauma-related procedures.
The company follows an integrated care delivery model, supported by advanced clinical infrastructure, critical care capabilities and academic training programs. Led by experienced medical professionals, Hannah Joseph Hospital maintains a balanced mix of inpatient and outpatient services, catering to both emergency and elective care requirements.
Financial Performance
For the period ended 31st March 2025, the company reported revenue of Rs. 77.53 cr., with an EBITDA margin of 26.47% and a PAT margin of 9.30%.
For the period ended 30th September 2025, revenue stood at Rs. 42.55 cr., with EBITDA margin improving to 27.38% and PAT margin rising to 12.03%, reflecting better operating leverage and case mix.
According to Mr. Sunil Kumar Manocha, Founder & Director of Capital Square Advisors Private Limited, Hannah Joseph Hospital operates a tertiary care facility in its core market with a focused presence across neurosciences, cardiology, trauma and critical care. Supported by accredited operations and participation in government insurance schemes, the hospital is positioned to deploy incremental capital towards capacity enhancement and service integration initiatives, which are expected to improve patient throughput, expand clinical offerings and support growth in both inpatient and outpatient revenues.
To finance its growth, Hannah Joseph Hospital is going public with its IPO to raise a fresh issue of Rs. 42 crore, which will open for subscription on Thursday, 22nd January 2026 and will close on Tuesday, 27th January 2026. The issue comprises 60,00,000 equity shares of Rs. 67–70 per share with a face value of Rs. 10 per share. The issue will be listed on the BSE SME platform.
The anchor portion opens on Wednesday, 21st January 2026, while the issue will open on Thursday, 22nd January 2026 and close on Tuesday, 27th January 2026.
The net proceeds from the IPO will be utilised towards capital expenditure for establishing a Radiation Oncology Centre and general corporate purposes.
The issue is managed by Capital Square Advisors Pvt. Ltd.
